- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02039895
Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma (HITS)
Radiation therapy, Total skin electron beam therapy (TSEBT), achieves a high response rate and is an effective treatment for cutaneous T-cell lymphoma affecting the superficial region. One the most widely used TSEBT techniques consists of six dual fields initially developed at Stanford University. However, deviations occur from the prescription dose up to 40% and the surface dose inhomogeneity as much as 90% in body areas such as the perineum and eyelid.
Helical tomotherapy (HT) has advantages in irradiating extended volumes with treatment length of up to 160 cm, continuously in a helical pattern without the need for field junction. Using HT, an image-guided intensity-modulated radiotherapy, to replace conventional TSEBT technique to increase dose delivery and decrease toxicities possibly. Recently, we published the possibility of helical irradiation of the total skin (HITS) by physical proving and showed the clinical results of HITS successfully for a woman with T cell lymphoma failure by chemotherapy, topic UV irradiation and local radiotherapy (RT) to overcome the surface dose inhomogeneity by conventional RT.
Here, investigators will enroll the stage I-IV cutaneous T-cell lymphoma (CTCL) of International Society Cutaneous Lymphomas (ISCL)/U.S. Cutaneous Lymphoma Consortium (USCLC)/European Organization for Research & Treatment of Cancer (EORTC), patients who are candidates for TSEBT by recommendation of National Comprehensive Cancer Network Guidelines (Version 4.2011, Mycosis fungoid/Sezary syndrome) or who are refractory or not feasible to the topic UV irradiation, Interferon alpha, psoralen plus ultraviolet A photochemotherapy, and Accutane® (Isotretinoin) or chemotherapy to receive HITS to replace TSEBT. Additionally, we will compare the advantages and disadvantages between the plan of HT and conventional RT for TSEBT.
Studieöversikt
Studietyp
Inskrivning (Förväntat)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
-
New Taipei City, Taiwan, 220
- Far Eastern Memorial Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- The stage I-IV cutaneous T-cell lymphoma (CTCL) of International Society Cutaneous Lymphomas (ISCL) and U.S. Cutaneous Lymphoma Consortium (USCLC)/European Organization for Research & Treatment of Cancer (EORTC), patients who are candidates for TSEB by recommendation of National Comprehensive Cancer Network Guidelines (Version 4.2011, Mycosis fungoid/Sezary syndrome)
- Patients who are refractory or not feasible to the topic UV irradiation, Interferon alpha, psoralen plus ultraviolet A photochemotherapy, and Isotretinoin or chemotherapy.
- Eligibility criteria included the following: Karnofsky status 70% or greater; creatinine clearance greater than 50 mL/min; cardiac left ventricular ejection fraction 50% or greater; aspartate aminotransferase and alanine aminotransferase less than 2.5 times the upper limits of institutional normal; adequate pulmonary function as shown by a forced expiratory volume of greater than 60%; and peripheral neuropathy grade 1 or lower. Patients were preassessed for their ability to lie supine for approximately 1 hour.
- They had to be previously untreated TSEBT. Prior local radiation was permitted.
- All patients voluntarily signed an informed consent form approved by the Institutional Review Board.
Exclusion Criteria:
- Patient were prior treated by TSEBT for CTCL, another type of cancer, abnormal cardiac function (systolic ejection fraction < 50 percent or an abnormal stress test), chronic respiratory disease (vital capacity or carbon monoxide diffusion, < 50 percent of normal), abnormal liver function (serum bilirubin, > 2.0 mg per deciliter [>35 micromol per liter]; or serum aminotransferase values more than four times the normal value), and psychiatric disease.
- Females who are pregnant/lactating or planning to be pregnant.
- Patients with other systemic diseases that required long-term (≥ 2 weeks) usage of glucocorticosteroid or immunosuppressant agent(s) within 4 weeks prior to the initiation of study treatment.
- Child or handicap are excluded
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: HITS for CTCL
Cutaneous T-cell lymphoma treats by helical irradiation of the total skin (HITS) using helical tomotherapy
|
Helical irradiation of the total skin by helical tomotherapy
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Participants with Serious and Non-Serious Adverse Events
Tidsram: 3 months
|
participants will be followed from the duration of RT to RT finish 1 month, an expected average of 3 ms
|
3 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Time to Disease Progression
Tidsram: Up to 24 ms
|
Up to 24 ms
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Chen-Hsi Hsieh, M.D., Ph.D., Far Eastern Memorial Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- FEMH-IRB-102135-F
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kutant T-cellslymfom
-
National Cancer Institute (NCI)AvslutadPerifert T-cellslymfom (PTCL) | T-cell prolymfocytisk leukemi | Kutant T-cellslymfom (CTCL) | T-cellslymfom återfallit | Vuxen T-cellsleukemi (ATL)Förenta staterna
-
National Cancer Institute (NCI)IndragenHepatospleniskt T-cellslymfom | Enteropati-associerat T-cellslymfom | Vuxen T-cell leukemi/lymfom | Extranodalt NK-/T-cellslymfom, nästyp | Monomorft epiteliotrofisk tarm T-cellslymfomFörenta staterna
-
CelgeneAvslutadPerifert T-cellslymfom | Vuxen T-cell leukemi-lymfomJapan
-
Novartis PharmaceuticalsAvslutadLeukemi-lymfom, vuxen T-cell | Kutant T-cellslymfomJapan
-
University of Alabama at BirminghamAvslutadAnaplastiskt storcelligt lymfom | Angioimmunoblastiskt T-cellslymfom | Perifera T-cellslymfom | Vuxen T-cell leukemi | Vuxen T-cellslymfom | Perifert T-cellslymfom Ospecificerat | Systemisk typ av T/Nullcell | Kutant t-cellslymfom med nodal/visceral sjukdomFörenta staterna
-
National Cancer Institute (NCI)AvslutadLymfom | Kutan | T-cellFörenta staterna
-
John ReneauRekryteringÅterkommande primärt kutant T-cells non-Hodgkin-lymfom | Återkommande vuxen T-cell leukemi/lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Refraktär vuxen T-cell leukemi/lymfomFörenta staterna
-
Otsuka Pharmaceutical Co., Ltd.Aktiv, inte rekryterandeÅterfallande eller refraktärt perifert T-cellslymfom (PTCL), Kutant T-cellslymfom (CTCL), Vuxen T-cellsleukemi/lymfom (ATLL)Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeRefraktärt mogen T-cell och NK-cell non-Hodgkin lymfom | Mogen T-cell och NK-cell non-Hodgkin lymfom | Återkommande moget T- och NK-cells non-Hodgkin-lymfom | Återkommande kutant T-cell non-Hodgkin lymfom | Refraktärt kutant T-cell non-Hodgkin lymfomFörenta staterna
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalOkändAkut myeloid leukemi | Angioimmunoblastiskt T-cellslymfom | Hepatospleniskt T-cellslymfom | Prekursor T-cell lymfoblastisk leukemi-lymfom | Extranodalt NK/T-cellslymfom, nästyp | T-cell prolymfocytisk leukemi | T-cell stor granulär lymfatisk leukemi | Perifert T-cellslymfom, NOS | Intestinalt T-cellslymfom...Kina
Kliniska prövningar på HITS
-
Chulalongkorn UniversityAvslutadAllergisk rinitThailand
-
Göteborg UniversitySahlgrenska University Hospital, SwedenAvslutad
-
Haukeland University HospitalRekryteringBipolär sjukdom | Schizofreni och relaterade sjukdomarNorge
-
Hip Innovation TechnologyRekryteringArtros i höftenKanada
-
University of Erlangen-Nürnberg Medical SchoolKlinikum NürnbergAvslutad
-
University of AdelaideRoyal Adelaide Hospital; University of South AustraliaAvslutad
-
Hasselt UniversityJessa HospitalAvslutad
-
Turku University HospitalUniversity of Turku; University of Helsinki; Academy of Finland; European Foundation... och andra samarbetspartnersOkändTyp 2-diabetes mellitus | Friska volontärerFinland
-
University of ZurichAvslutad
-
Hasselt UniversityJessa HospitalOkänd